Trial Profile
A Randomized (1:1), Double-blind, Multi-center, Placebo Controlled Study Evaluating Intensive Chemotherapy With Or Without Glasdegib (Pf-04449913) Or Azacitidine (Aza) With Or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Glasdegib (Primary) ; Azacitidine; Azacitidine; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BRIGHT; BRIGHT AML1019
- Sponsors Pfizer
- 04 Feb 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 24 Jan 2022 Status changed from active, no longer recruiting to completed.
- 24 Jan 2022 Status changed from active, no longer recruiting to completed.